Cited In for PMID: 34407342

Year	Number of Results
2021	13
2022	85
2023	91
2024	88
2025	83
2026	13

1

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.

2

Tumor-draining lymph nodes as immunologic hubs: rethinking nodal surgery in the era of checkpoint blockade in urologic cancers.

Yamamoto S, Higa K, Kurokawa K, Bamba H, Kanaoka S, Nakamura K. Yamamoto S, et al. Int Urol Nephrol. 2026 Apr 3. doi: 10.1007/s11255-026-05126-z. Online ahead of print. Int Urol Nephrol. 2026. PMID: 41933077 Review.

3

Initial and Repeat Metastasis-Directed Therapy in Systemic Therapy-Naïve Oligometastatic Renal Cell Carcinoma: Oncologic Outcomes and Risk-Based Stratification.

Yu J, Baek JY, Song W, Kang M, Sung HH, Jeon HG, Jeong BC, Jeon SS, Pyo HR, Park W, Seo SI. Yu J, et al. Ann Surg Oncol. 2026 Mar 17. doi: 10.1245/s10434-026-19451-1. Online ahead of print. Ann Surg Oncol. 2026. PMID: 41844996

4

Survival outcomes after surgical treatment for non-clear cell renal cell carcinoma with tumor thrombus extension: a population-based cohort study.

Cheaib JG, Rivera López CA, Cronin C, Alshak MN, El-Achkar A, Patel SH, Singla N. Cheaib JG, et al. World J Urol. 2026 Mar 7;44(1):225. doi: 10.1007/s00345-026-06285-5. World J Urol. 2026. PMID: 41793499

5

Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer.

Lee IT, Wang YL, Hong JH, Huang CY, Vo TTT, Lee WJ, Chiang CH. Lee IT, et al. Cell Commun Signal. 2026 Feb 28;24(1):209. doi: 10.1186/s12964-026-02770-x. Cell Commun Signal. 2026. PMID: 41761243 Free PMC article. Review.

6

Pattern of disease recurrence and outcomes after progression of high-risk renal cell carcinoma (RCC) patients treated with adjuvant immunotherapy.

Ciccarese C, Occhipinti D, Arduini D, Di Leo D, Neri A, Roca L, Messina G, Troisi P, Pedone RR, Fucile MA, Belletto R, Sardaro V, Ligato C, Ajdhoni R, Caliciotti F, Sighinolfi C, Tagliaferri L, Rocco B, Tortora G, Iacovelli R. Ciccarese C, et al. Cancer Immunol Immunother. 2026 Feb 25;75(3):85. doi: 10.1007/s00262-026-04331-0. Cancer Immunol Immunother. 2026. PMID: 41739194 Free PMC article.

7

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Johnson DB, Nassar AH, Aijaz A, Knight A, Zerey MM, Rini BI, Naqash AR, Sullivan RJ. Johnson DB, et al. Nat Rev Clin Oncol. 2026 Feb 18. doi: 10.1038/s41571-026-01123-4. Online ahead of print. Nat Rev Clin Oncol. 2026. PMID: 41708831 Review.

8

Local treatment for metastatic and primary sites in metastatic renal cell carcinoma in the combination immunotherapy era: a narrative review.

Abe J, Murashima T, Kojima S, Ueno T, Takei A, Nakai N, Akioka T, Kamoto T, Sawada A. Abe J, et al. Int J Clin Oncol. 2026 Feb 13. doi: 10.1007/s10147-026-02982-8. Online ahead of print. Int J Clin Oncol. 2026. PMID: 41686385 Review.

9

Association of immune checkpoint inhibitor-induced bullous pemphigoid with underlying cancer type: A lack of association with cancer tissue COL17A1 mutations and dysregulation.

Chang RC, Olbrich H, Wang YF, Gainer H, Curkovic N, Walunas TL, Shiu J, Goyal P, Mansini AP, Ludwig RJ, Amber KT. Chang RC, et al. JID Innov. 2026 Jan 13;6(2):100450. doi: 10.1016/j.xjidi.2026.100450. eCollection 2026 Mar. JID Innov. 2026. PMID: 41658267 Free PMC article.

10

Neoadjuvant immunotherapy for early-stage hepatocellular carcinoma: the arts and science.

Chan LL, Kung JWC, Chan SL. Chan LL, et al. ESMO Gastrointest Oncol. 2023 Nov 7;1:15-20. doi: 10.1016/j.esmogo.2023.08.001. eCollection 2023 Oct. ESMO Gastrointest Oncol. 2023. PMID: 41647284 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

355 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Cited In for PMID: 34407342

355 results

Results by year